With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing sales forecast for tardive dyskinesia (TD) drug Ingrezza commanded much of the investment community's attention after the company revealed its full-year 2024 results last week.